ReviewGeneral thoracic and cardiovascular surgery2012
Optimal radiotherapy for non-small-cell lung cancer: current progress and future challenges.
Review in General thoracic and cardiovascular surgery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Local control and survival after stereotactic body radiation therapy of early-stage lung cancer patients in Slovenia.Radiology and oncology · 2023Article
- Article
- Gold Nanoparticles as Radiosensitizers in Cancer Radiotherapy.International journal of nanomedicine · 2020Review
- Salvage video-assisted thoracoscopic lobectomy for isolated local relapse after stereotactic body radiotherapy for early stage non-small cell lung cancer: technical aspects and perioperative management.Journal of visualized surgery · 2017Article
- Inhibition of TGF-β signaling with halofuginone can enhance the antitumor effect of irradiation in Lewis lung cancer.OncoTargets and therapy · 2015Article
- Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients.Oncology letters · 2013Article
- Comparison of acute proton, photon, and low-dose priming effects on genes associated with extracellular matrix and adhesion molecules in the lungs.Fibrogenesis & tissue repair · 2013Article
- Does the couse of astragalus-containing chinese herbal prescriptions and radiotherapy benefit to non-small-cell lung cancer treatment: a meta-analysis of randomized trials.Evidence-based complementary and alternative medicine : eCAM · 2013Review
- Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: When and Why Is It Appropriate Therapy?Journal of the advanced practitioner in oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy has a key role in treating lung cancer. Advances in physics and computer technology have improved radiation delivery systems. With innovations in the radiation therapy of non-small-cell lung cancer (NSCLC), new strategies have emerged, such as intensity-modulated radiation therapy, stereotactic body radiation therapy, and particle therapy. Compared with previous methods, these newer technologies can deliver even higher doses precisely to the tumor while minimizing doses to normal tissues, which should lead to better tumor control with less toxicity. In patients with stage I NSCLC, stereotactic body radiation therapy is highly effective and may achieve local control and survival equivalent to that achieved with surgery. In patients with stage III NSCLC, dose escalation has been investigated using three-dimensional conformal radiation therapy, intensity-modulated radiation therapy, and particle therapy. The results from ongoing randomized trials on both patient populations are awaited. It is important to generate new hypotheses and to explore newer radiotherapy approaches to overcome NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.